Foxp3(+)CD4(+) regulatory T (Treg) cells are thought to express negligible levels of effector cytokines, and inhibit immune responses and inflammation. Here, we have identified a population of IL-8(+)Foxp3(+)CD4(+) T cells in human peripheral blood, which is selectively increased in the microenvironments of ulcerative colitis and colon carcinoma. Phenotypically, this population is minimally overlapping with IL-17(+)Foxp3(+)CD4(+) T cells, and is different from IL-8(-)Foxp3(+)CD4(+) T cells in the same microenvironment. 40-60% of IL-8(+)Foxp3(+)CD4(+) T cells exhibit naive phenotype and express CD127, whereas IL-8(-)Foxp3(+)CD4(+) cells are basically memory T cells and express minimal CD127. The levels of CXCR5 expression are higher in IL-8(+)Foxp3(+) cells than in IL-8(-)Foxp3(+) cells. IL-2 and TGFβ induce IL-8(+)Foxp3(+) T cells. Exogenous Foxp3 expression promotes IL-8(+)Foxp3(+) T cells and inhibits effector cytokine IFNγ and IL-2 expression. Furthermore, Foxp3 binds to IL-8 proximal promoter and increases its activity. Functionally, IL-8(+)Foxp3(+) T cells inhibit T cell proliferation and effector cytokine production, but stimulate inflammatory cytokine production in the colon tissues, and promote neutrophil trafficking through IL-8. Thus, IL-8(+)Foxp3(+) cells may be an "inflammatory" Treg subset, and possess inflammatory and immunosuppressive dual biological activities. Given their dual roles and localization, these cells may be in a unique position to support tumor initiation and development in human chronic inflammatory environment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007964PMC
http://dx.doi.org/10.1080/2162402X.2015.1105430DOI Listing

Publication Analysis

Top Keywords

il-8+foxp3+ cells
20
cells
15
microenvironments ulcerative
8
ulcerative colitis
8
colitis colon
8
colon carcinoma
8
il-8+foxp3+cd4+ cells
8
il-8-foxp3+cd4+ cells
8
effector cytokine
8
cytokine production
8

Similar Publications

Problem: Regulatory B-cells (Bregs, CD19CD24CD38) are a specialized B-cell subset that suppresses immune responses and potentially contribute to the maintenance of an immune-privileged environment for fetal development during pregnancy. However, little is known about the surrounding immunological environment of Bregs in gestational physiology. The relationship of regulatory T-cells (Tregs, CD4CD25CD127FoxP3) to Bregs in coordinating immunoregulation during pregnancy is unknown.

View Article and Find Full Text PDF

To investigate the regulatory mechanism of indoleamine 2, 3-dioxygenase (IDO) in T lymphocyte differentiation and its role in promoting the growth of gastric cancer (GC) cells through the PI3K/Akt/mTOR pathway. GC cell lines (MFC and NCI-N87) and PBMC cells were co-cultured and IDO inhibitor 1-methyl-tryptophan (1-MT) was added. The proliferation was detected by CCK-8, the apoptosis was detected by flow cytometry, and the contents of TNF-α, IL-1β, IL-6, IL-8, and INF-γ were detected by ELISA.

View Article and Find Full Text PDF

Background: IL-2 regulates T cell differentiation: low-dose IL-2 induces immunoregulatory Treg differentiation, while high-dose IL-2 acts as a potent activator of cytotoxic T cells and NK cells. Therefore, high-dose IL-2 has been studied for use in cancer immunotherapy. We aimed to utilize low-dose IL-2 to treat inflammatory diseases such as obesity and insulin resistance, which involve low-grade chronic inflammation.

View Article and Find Full Text PDF
Article Synopsis
  • Lanthionine synthetase C-like 2 (LANCL2) is identified as a key immunoregulatory target in treating autoimmune diseases like systemic lupus erythematosus (SLE), with the investigational drug NIM-1324 aimed at improving patient outcomes.
  • In laboratory models, mice lacking LANCL2 exhibited severe symptoms of inflammation, while treatment with NIM-1324 enhanced regulatory T cell populations and reduced harmful inflammatory T cells, leading to overall better health markers.
  • NIM-1324 also showed efficacy in human immune cells from SLE patients, lowering pro-inflammatory cytokines and supporting a more balanced immune response, indicating its potential as a therapeutic option.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the immune response differences in patients with recurrent vulvovaginal candidiasis (RVVC) compared to healthy women, highlighting reduced neutrophil function and altered immune cell activation.
  • Researchers analyzed vaginal tissue for immune-related gene expression and serum levels of key proteins, finding significant changes in cytokine profiles and lower levels of the immune protein mannose-binding lectin (MBL) in RVVC patients.
  • Results suggest that these immune alterations may contribute to the inflammatory responses observed in RVVC, indicating an imbalance in both innate and adaptive immunity against Candida infections.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!